Structure Therapeutics Inc. Sponsored ADR $GPCR is Avoro Capital Advisors LLC’s 8th Largest Position

Avoro Capital Advisors LLC grew its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 21.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 6,555,555 shares of the company’s stock after acquiring an additional 1,150,000 shares during the quarter. Structure Therapeutics makes up approximately 4.4% of Avoro Capital Advisors LLC’s investment portfolio, making the stock its 8th biggest position. Avoro Capital Advisors LLC owned approximately 0.09% of Structure Therapeutics worth $455,939,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. State of Wyoming purchased a new stake in shares of Structure Therapeutics in the second quarter valued at approximately $28,000. EverSource Wealth Advisors LLC grew its position in Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after acquiring an additional 901 shares during the period. CWM LLC grew its position in Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 125 shares during the period. ANTIPODES PARTNERS Ltd grew its position in Structure Therapeutics by 39.1% in the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after acquiring an additional 1,146 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in Structure Therapeutics in the fourth quarter worth approximately $127,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on GPCR shares. Citizens Jmp lowered their price objective on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. BMO Capital Markets set a $145.00 price objective on Structure Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. HC Wainwright lowered their price objective on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Finally, Wolfe Research started coverage on Structure Therapeutics in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $106.75.

Structure Therapeutics Stock Down 0.4%

GPCR opened at $42.91 on Wednesday. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $15.80 and a 52 week high of $94.90. The business has a fifty day simple moving average of $43.22 and a 200-day simple moving average of $57.45. The firm has a market cap of $3.05 billion, a P/E ratio of -49.32 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04. Sell-side analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.